Bostal Drug Delivery Co., Ltd. announced that it has received $31.4 million in funding from Huatai Zijin Investment Co. Ltd, Guangzhou Chuangyu Investment Management Co., Ltd., Guangzhou Jet Bio-Filtration Co., Ltd., Guangzhou Sanmei Investment Management Center (Limited Partnership)
April 18, 2022
Share
Bostal Drug Delivery Co., Ltd. announced that it has received $31.4 million in its Series B+ round of funding led by Huatai Zijin Investment Co. Ltd on April 19, 2022. The transaction included participation from Guangzhou Chuangyu Investment Management Co., Ltd., Guangzhou Jet Bio-Filtration Co., Ltd., and Guangzhou Sanmei Investment Management Center (Limited Partnership).
Guangzhou Jet Bio-Filtration Co Ltd is a China-based company principally engaged in the research, development, production and sales of cell culture and related liquid handling life science consumables. The Company's main products include two categories of life science consumables, biological culture and liquid handling, as well as a small number of biological reagents, small laboratory instruments, protective equipment, medical devices and others. The Company's products are used in fields such as biomedicine, molecular diagnosis, medical protection, cell therapy, and biological research. The Company distributes its products within the domestic market and to overseas markets.
Bostal Drug Delivery Co., Ltd. announced that it has received $31.4 million in funding from Huatai Zijin Investment Co. Ltd, Guangzhou Chuangyu Investment Management Co., Ltd., Guangzhou Jet Bio-Filtration Co., Ltd., Guangzhou Sanmei Investment Management Center (Limited Partnership)
GUANGZHOU JET BIO-FILTRATION CO., LTD. 
